Trials / Completed
CompletedNCT00530062
Comparison of Single-Dose Efficacy of an Albuterol Breath-Actuated Inhaler (Albuterol-HFA-BAI) Versus an Albuterol Metered-Dose Inhaler (Albuterol-HFA-MDI) in Participants With Asthma
Comparison of Single-Dose Efficacy of Albuterol-HFA-BAI and Albuterol-HFA-MDI in Asthmatics With Poor Inhaler Coordinating Ability
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 7 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is a research study designed to compare the single-dose efficacy of albuterol-hydrofluoroalkane-breath-actuated inhaler (HFA-BAI) and albuterol-HFA-metered-dose inhaler (MDI) in asthmatics with poor inhaler coordinating abilities.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Albuterol-HFA-MDI | Inhalation Aerosols, 90 mcg, 1 dose per treatment period |
| DRUG | Albuterol-HFA-BAI | Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period. |
Timeline
- Start date
- 2007-07-25
- Primary completion
- 2008-10-24
- Completion
- 2008-10-24
- First posted
- 2007-09-17
- Last updated
- 2022-09-07
- Results posted
- 2022-08-31
Locations
5 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00530062. Inclusion in this directory is not an endorsement.